Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
About this item
Full title
Author / Creator
IRIS Investigators , Hochhaus, Andreas , Larson, Richard A , Guilhot, François , Radich, Jerald P , Branford, Susan , Hughes, Timothy P , Baccarani, Michele , Deininger, Michael W , Cervantes, Francisco , Fujihara, Satoko , Ortmann, Christine-Elke , Menssen, Hans D , Kantarjian, Hagop , O’Brien, Stephen G and Druker, Brian J
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
After nearly 11 years of follow-up, long-term administration of imatinib was shown to be associated with prolonged control of chronic myeloid leukemia and no cumulative or late toxic effects have emerged.
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm that is characterized by the Philadelphia (Ph) chromosome and driven by its pr...
Alternative Titles
Full title
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5901965
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5901965
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1609324
